KS

Kannan Suresh

Active Director Director DIN 02955263
DIN 02955263 First appointment Jun 2010 Primary industry Trading
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2010
Shareholding value •••• Premium profile

About Kannan Suresh

Data last updated:

Kannan Suresh is a Director at Citius Biotech Private Limited (since 2010). The company operates in Trading. Citius Biotech Private Limited reported revenue of ₹17.9 Lakh (FY 2025).

DIN 02955263
Primary Designation Director
Industry Trading
First Appointment 03 Jun 2010
Oldest Company Age 16 yrs
Largest company Citius Biotech Private Limited · ₹17.9 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Citius Biotech Private Limited U74900TN2010PTC075983
Director03 Jun 20102010₹17.9 Lakh (FY 2025)Active

Board colleagues of Kannan Suresh

Directorship timeline

Open interactive timeline →
Citius Biotech Private Limited
Premium access

Shareholding and investment profile for Kannan Suresh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kannan Suresh

Kannan Suresh currently holds 1 directorship: Citius Biotech Private Limited (Director, since 03 Jun 2010, revenue ₹17.9 Lakh (FY 2025)).

Kannan Suresh was first appointed on 03 Jun 2010 as Director at Citius Biotech Private Limited.

The current boards of Kannan Suresh's companies include Mohankumar Jaganathan (Citius Biotech Private Limited), Saravanan Ethirajulu (Citius Biotech Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available